Clinical trial • Phase I • Oncology
IAG933 for Mesothelioma | Other solid tumours with Hippo pathway alterations
Phase I trial of IAG933 for Mesothelioma | Other solid tumours with Hippo pathway alterations. 62 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Mesothelioma | Other solid tumours with Hippo pathway alterations
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 20-12-2023
- First CTIS Authorization Date
- 20-02-2024
Trial design
Phase I trial across 6 sites in Netherlands, France, Spain and others.
- Biomarker Stratified
- True, biomarker: Hippo pathway molecular alterations
- Target Sample Size
- 62
Eligibility
Recruits 62 Vulnerable population selected; no details on consent or assent available..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent available.
Recruitment
- Planned Sample Size
- 62
- Recruitment Window Months
- 59
Geography
- Total Number Of Sites
- 6
- Total Number Of Participants
- 89
Netherlands
- Latest Decision Or Authorization Date
- 20-02-2024
- Number Of Sites
- 1
- Number Of Participants
- 10
Sites
- Site Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Department Name
- 7001: Pulmonary Department
- Principal Investigator Name
- Joachim Aerts
- Principal Investigator Email
- j.aerts@erasmusmc.nl
- Contact Person Name
- Joachim Aerts
- Contact Person Email
- j.aerts@erasmusmc.nl
France
- Latest Decision Or Authorization Date
- 26-02-2024
- Number Of Sites
- 1
- Number Of Participants
- 8
Sites
- Site Name
- Institut Gustave Roussy
- Department Name
- 4001: Innovations Thérapeutiques et Essais Précoces
- Principal Investigator Name
- Christophe MASSARD
- Principal Investigator Email
- Christophe.MASSARD@gustaveroussy.fr
- Contact Person Name
- Christophe MASSARD
- Contact Person Email
- Christophe.MASSARD@gustaveroussy.fr
Spain
- Latest Decision Or Authorization Date
- 18-03-2024
- Number Of Sites
- 1
- Number Of Participants
- 23
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- 8001: Oncology
- Principal Investigator Name
- Elena Garralda Cabanas
- Principal Investigator Email
- egarralda@vhio.net
- Contact Person Name
- Elena Garralda Cabanas
- Contact Person Email
- egarralda@vhio.net
Italy
- Latest Decision Or Authorization Date
- 15-03-2024
- Number Of Sites
- 2
- Number Of Participants
- 40
Sites
- Site Name
- Humanitas Research Hospital
- Department Name
- 6001: U.O. di Oncologia Medica ed Ematologia
- Principal Investigator Name
- Armando Santoro
- Principal Investigator Email
- armando.santoro@humanitas.it
- Contact Person Name
- Armando Santoro
- Contact Person Email
- armando.santoro@humanitas.it
- Site Name
- Fondazione IRCCS Istituto Nazionale Dei Tumori
- Department Name
- 6002: S.C. Oncologia Medica 1
- Principal Investigator Name
- Matteo Duca
- Principal Investigator Email
- matteo.duca@istitutotumori.mi.it
- Contact Person Name
- Matteo Duca
- Contact Person Email
- matteo.duca@istitutotumori.mi.it
Germany
- Latest Decision Or Authorization Date
- 23-02-2024
- Number Of Sites
- 1
- Number Of Participants
- 8
Sites
- Site Name
- Universitaetsklinikum Essen AöR
- Department Name
- 3001: Westdeutsches Tumorzentrum
- Principal Investigator Name
- Martin Metzenmacher
- Principal Investigator Email
- martin.metzenmacher@uk-essen.de
- Contact Person Name
- Martin Metzenmacher
- Contact Person Email
- martin.metzenmacher@uk-essen.de
Sponsor
Primary sponsor
- Full Name
- Novartis Pharma AG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Switzerland
Investigational products
- Investigational Product Name
- IAG933
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)